Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1

Conditions

Pancreatic Neoplasms 10Colorectal Neoplasms 10Neoplasm Metastasis 7Neuroblastoma 4Rhabdomyosarcoma 3Lung Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Rectal Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Neuroendocrine 2Biliary Tract Neoplasms 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Refractory Solid Tumors 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Medulloblastoma 1Malignant mesenchymal tumor 1Intestinal Neoplasms 1Gastrointestinal Neoplasms 1

Interventions

Radiotherapy 5Oxaliplatin 5Nivolumab 5Fluorouracil 5Cetuximab 5Leucovorin 4Magnetic Resonance Spectroscopy 3Bevacizumab 3sintilimab 2pembrolizumab 2fludarabine 2encorafenib 2aldesleukin 2Tomography, X-Ray Computed 2Specimen Handling 2Pemetrexed 2Magnetic Resonance Imaging 2Irinotecan 2Gemcitabine 2Folfox protocol 2Electrocardiography 2Drug Therapy 2Dexamethasone 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Biopsy 2ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rectal Neoplasms × Irinotecan × 30 days × Clear all
NCT00492999 2026-06-03

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
64 enrolled
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡